TargetBeta
VDR
vitamin D receptor · also NR1I1, PPP1R163 · Protein phosphatase 1 regulatory subunits
2 programs in company-led studies act on VDR, from 2 companies: 1 in phase 3, 1 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (2 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| calcipotrienerule | LEO Pharma | phase 4 | 390 running | – | ChEMBL |
| Modified-release Calcifediol Capsulerule | OPKO Health | phase 3 | 101 running | – | ChEMBL |
Conditions their studies are in
- Alopecia Areata, 1 program
- Breast Neoplasms, 1 program
- COVID-19, 1 program
- Hyperparathyroidism, Secondary, 1 program
- Psoriasis, 1 program
- Renal Insufficiency, Chronic, 1 program
- Vitamin D Deficiency, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Oct 2027Modified-release Calcifediol Capsule · OPKO Health · phase 3 · NCT07494045
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.